BAIAP2L2 and posterior cortical atrophy: Compared to traditional PCa biomarkers such as prostate-specific antigen (PSA) and androgen receptor (AR) variants, BAIAP2L2 may offer complementary value, particularly in cases where PSA levels lack specificity or AR variants contribute to therapy resistance.